full free access: (references Dr Folkman 1971) Antiangiogenic Therapies in Epithelial Ovarian Cancer (printer-friendly)

Source: Posted: 03/22/2011; Cancer Control. 2011;18(1):31-43. © 2011 H. Lee Moffitt Cancer Center and Research Institute, Inc.

Expert Perspectives in Oncology: Contemporary Approaches in Targeting Angiogenesis prIME Oncology

Note: requires registration to view (free), also speaks about ICON 7 (ovarian cancer/avastin trial) Module Six Practical Considerations in Patient Management Involving Antiangiogenic Therapy

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium

Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada; †Juravinski Cancer Centre, McMaster University,Hamilton, Ontario, Canada; ‡Fox Chase Cancer Center, Philadelphia, PA; and §National Cancer Institute, Bethesda, MD.

Abstract

OBJECTIVES: Antiangiogenic strategies have demonstrated efficacy in epithelial ovarian cancer (EOC). Sorafenib is a novel multitargeted kinase inhibitor with antiangiogenic activity. Gemcitabine has known activity against EOC. A phase 1 clinical trial of this combination suggested activity in ovarian cancer with no dose-limiting toxicity. This phase 2 study was designed to examine the safety and efficacy of gemcitabine and sorafenib in patients with recurrent EOC.

CONCLUSION: This trial of gemcitabine and sorafenib in recurrent EOC did not meet its primary efficacy end point, but the combination was associated with encouraging rates of prolonged stable disease and CA-125 response.

full access: Tumor Angiogenesis: Insights and Innovations (not specific to ovarian cancer)

"These two ongoing theories showcase the current problems in the field of antiangiogenic research in cancer. After several years of clinical trials, it appears that targeting one angiogenic factor is not enough to permanently halt neovascularization in most tumors. Although these results were initially disheartening, they also opened up the possibility of other angiostatic therapies.
Many clinical trials now use existing chemotherapeutic drugs or radiation along with antiangiogenic drugs. This two-front attack has had more
success than antiangiogenic drugs or chemotherapy alone in a majority of patients."

2010: Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer : The Lancet Oncology (abstract only)

Note: abstract/full access is by subscription/$$